A Phase 2 interventional study of olaparib in Colorectal Cancer, sponsored by AstraZeneca. Completed at 8 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-11-09.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colorectal Neoplasms by AstraZeneca — 2 open to participants now, 8 under way, none of them phase 3. Colorectal Neoplasms · AstraZeneca.
Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 21st largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2009, is one of 12 in phase 2, and was the 12th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →2 of the 29 studies in Colorectal Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Canada, China and 11 more countries
Ages 18–130
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 3
First in 2003; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 69 across the 28 interventional studies, 140 across the 1 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
6 of the studies in Colorectal Neoplasms by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
| NCT06792695AstraZenecaA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | 2027-06-30 |
| NCT06218914AstraZenecaPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | 2027-08-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 29 studies in Colorectal Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MSI - H arm
Drug: olaparib
400 mg po bid continuously
Tumour Response
Tumour response is the number of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1)
Time frame: From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months
Progression Free Survival
Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.
Time frame: From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months
Overall Survival
Overall survival is defined as the duration from first dose till death from any cause. In absence of death, the time is calculated from first dose till the date subject last known to be alive
Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed up to 35 months
Target accrual: 54 subjects. MSI-H group: 15; non-MSI-H group: 39. Pre-planned interim analysis of the non-MSI-H cohort, after 17 patients, stopped recruitment into that cohort. Recruitment to the MSI-H cohort continued.
| Milestone | MSI-H | Non-MSI-H |
|---|---|---|
| Started | 13 | 20 |
| Completed | 0 | 0 |
| Not completed | 13 | 20 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 9 | 18 |
| Withdrew: Toxicity | 0 | 1 |
| Withdrew: End of treatment form was not collected | 1 | 0 |
Tumour response is the number of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1)
| Percentage of Participants | MSI-H | Non-MSI-H |
|---|---|---|
| Tumour Response | 0 (0 to 25) | 0 (0 to 17) |
Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.
| days | MSI-H | Non-MSI-H |
|---|---|---|
| Progression Free Survival | 61 (52 to 360) | 55 (49 to 56) |
Overall survival is defined as the duration from first dose till death from any cause. In absence of death, the time is calculated from first dose till the date subject last known to be alive
| days | MSI-H | Non-MSI-H |
|---|---|---|
| Overall Survival | 248 (121 to 554) | 290.5 (157 to 429) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSI-H | — | 6/13 (46.2%) | 12/13 (92.3%) |
| Non-MSI-H | — | 3/20 (15%) | 20/20 (100%) |
| Event | MSI-H | Non-MSI-H |
|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 2/13 | 0/20 |
| HydronephrosisRenal and urinary disorders | 2/13 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 1/13 | 0/20 |
| Nodal rhythmCardiac disorders | 1/13 | 0/20 |
| Abdominal painGastrointestinal disorders | 1/13 | 0/20 |
| AscitesGastrointestinal disorders | 1/13 | 0/20 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/13 | 0/20 |
| Intestinal obstructionGastrointestinal disorders | 1/13 | 0/20 |
| Mucosal inflammationGeneral disorders | 1/13 | 0/20 |
| Oedema peripheralGeneral disorders | 1/13 | 0/20 |
| Event | MSI-H | Non-MSI-H |
|---|---|---|
| NauseaGastrointestinal disorders | 8/13 | 15/20 |
| AnaemiaBlood and lymphatic system disorders | 6/13 | 7/20 |
| VomitingGastrointestinal disorders | 6/13 | 9/20 |
| FatigueGeneral disorders | 5/13 | 8/20 |
| ConstipationGastrointestinal disorders | 5/13 | 3/20 |
| DiarrhoeaGastrointestinal disorders | 2/13 | 5/20 |
| AnorexiaMetabolism and nutrition disorders | 3/13 | 5/20 |
| Abdominal painGastrointestinal disorders | 3/13 | 4/20 |
| DizzinessNervous system disorders | 3/13 | 1/20 |
| RashSkin and subcutaneous tissue disorders | 3/13 | 3/20 |
| Age, Continuous(years) | MSI-H | Non-MSI-H | Total |
|---|---|---|---|
| Mean | 51.77 ± 9.37 | 61.80 ± 11.46 | 57.85 ± 11.65 |
| Sex: Female, Male(Participants) | MSI-H | Non-MSI-H | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 7 | 11 | 18 |
| Race/Ethnicity, Customized(Participants) | MSI-H | Non-MSI-H | Total |
|---|---|---|---|
| White | 10 | 19 | 29 |
| Black or African American | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Other | 1 | 1 | 2 |
The record gives a start of May 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 4 years 8 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib